Ongoing clinical trials should clarify optimal axilla management and treatment de-escalation options for patients with normal axillary ultrasound findings after neoadjuvant chemotherapy.
This analysis was undertaken to determine whether patient and disease characteristics can predict which patients will benefit from abemaciclib.
The CTS5 model is based on nodal status, tumor size, 3 categories of tumor grade, and age as a continuous variable.
At a previously reported median follow-up of 5 years, no DFS difference was detected between patients in the 2 study groups. This analysis was performed after a median follow-up of 9.8 years.
Study findings indicate that margin widths of at least 2 mm are associated with reduced risk of ipsilateral breast failure compared with narrower but uninvolved margins.
Translating these findings into clinical practice will require careful conversations with patients to weigh toxicity and potential benefits for each individual.
Further follow-up should help to clarify the safety and benefits of OFS for late breast cancer OS.
Elevated COX2 levels are associated with breast cancer progression. COX2 is transcriptionally regulated and enhances the aromatase pathway, especially in estrogen receptor-positive tumors.
Patients with stage II to III HER2+ breast cancer underwent tumor biopsy and were then randomly assigned to receive paclitaxel plus trastuzumab alone or with lapatinib for 16 weeks before surgery.
The findings support the use of pCR as a primary endpoint for accelerated approval of new drugs when EFS is evaluated in the relevant patient population.
Patients were randomly assigned to receive fulvestrant, fulvestrant plus continuous daily vistusertib, fulvestrant plus intermittent vistusertib, or fulvestrant plus everolimus.
Long non-coding RNA bound to ESR-1 might contribute to late-stage HR+ breast cancer relapse, researchers reported.
Neither adapted DFS nor OS differed between the groups in multivariate analyses adjusted for patient and tumor variables and chemotherapy.
A total of 159 recurrent CNA regions were identified. ERBB2 amplification was associated with high pCR, but the association fell to insignificance after correcting for ERBB2 expression.
Preclinical studies suggest that radiotherapy's pro-immunogenic effects might improve the antitumor efficacy of immune checkpoint inhibition.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Pembrolizumab and Chemotherapy Combination Significantly Improves PFS in NSCLC
- Daratumumab and Elotuzumab: Potential mAb Therapies for Multiple Myeloma
- Sex Hormone Levels Significantly Affect Treatment-Free Survival in Chronic Lymphocytic Leukemia
- Pediatric CML: Life-Long Considerations With TKI Therapy
- Reducing Dose Intensity May Be Associated with Shortened PFS in Waldenstrom Macroglobulinemia
- Nelarabine May Improve Disease-Free Survival in Pediatric and Young Adult T-cell ALL
- Lung Cancer Screening Rates Inadequate in United States Despite USPSTF Recommendations
- Can Oncolytic Viruses Improve Immunotherapies?
- Cognitive Behavioral Therapy Compared With Acupuncture for Insomnia in Cancer Survivors
- CYCORE System May Improve Radiotherapy-Associated Symptoms in Head and Neck Cancer